Presentation is loading. Please wait.

Presentation is loading. Please wait.

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP,

Similar presentations


Presentation on theme: "Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP,"— Presentation transcript:

1 Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP, Cliona McDowell, PhD, Sara Busacca, PhD, Glen Webb, MSc, Brian Moulton, PhD, Andrew Cakana, FIBMS, FRCP, Kenneth J. O’Byrne, PhD, MD, Jan V. Meerbeeck, PhD, MD, Paul Donnellan, MB, FRCPI, John McCaffrey, MD, FRCPI, Paul Baas, PhD  Journal of Thoracic Oncology  Volume 7, Issue 9, Pages (September 2012) DOI: /JTO.0b013e318260dfb9 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 A, Kaplan–Meier for disease progression—first line patients, median time to progression was 2.23 months (95% confidence limits 1.15–4.76). B, Kaplan–Meier for overall survival—first line patients. Median overall survival was months (95% confidence limits 1.77–not applicable). C, Kaplan–Meier for disease progression—second line patients. Median time to progression was 2.1 months (95% confidence limits 1.84–2.07). D, Kaplan–Meier for overall survival—second line patients. Median overall survival was 5.78 months (95% confidence limits 3.12–9.43). Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318260dfb9) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Noxa expression measured by immunohistochemistry associated with mesothelioma archival diagnostic biopsies. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e318260dfb9) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions


Download ppt "Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP,"

Similar presentations


Ads by Google